Advances in the systemic treatment of triple-negative breast cancer

  • J.M. Lebert Memorial University of Newfoundland
  • R. Lester Memorial University of Newfoundland
  • E. Powell Memorial University of Newfoundland
  • M. Seal Memorial University of Newfoundland
  • J. McCarthy Memorial University of Newfoundland
Keywords: Breast cancer, triple-negative breast cancer

Abstract

Triple-negative breast cancer constitutes a heterogeneous group of malignancies that are often aggressive and associated with a poor prognosis. Molecular characterization, while not a standard of care, can further subtype triple-negative breast cancer and provide insight into prognostication and behaviour. Optimal chemotherapy regimens have yet to be established; however, there have been advances in the systemic treatment of triple-negative breast cancer in the neoadjuvant, adjuvant, and metastatic settings. In this review, we discuss evidence for the potential benefit of neoadjuvant platinum-based chemotherapy, adjuvant combination chemotherapy with weekly paclitaxel, and BRCA mutation–directed therapy in the metastatic setting. The role for adjuvant capecitabine in patients who do not achieve a pathologic complete response with neoadjuvant chemotherapy is reviewed. Future directions and data concerning novel targeted agents are reviewed, including the most recent data on parp [poly (adp-ribose) polymerase] inhibitors, antiandrogen agents, and immunotherapy.

Author Biography

M. Seal, Memorial University of Newfoundland

 

Published
2018-06-14
How to Cite
Lebert, J., Lester, R., Powell, E., Seal, M., & McCarthy, J. (2018). Advances in the systemic treatment of triple-negative breast cancer. Current Oncology, 25, S142-S150. https://doi.org/10.3747/co.25.3954